<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/Reference</th>
<th>Vote</th>
</tr>
</thead>
</table>
| **Internal request** | Based on the available data and the recent FDA approval, the panel consensus was to include atezolizumab as a first-line chemotherapy for patients who are cisplatin-ineligible with locally advanced or metastatic disease. Atezolizumab was added as a category 2A option for the following settings:  
  - Bladder Cancer  
  - Upper GU Tract Tumors: Renal Pelvis  
  - Upper GU Tract Tumors: Urothelial carcinoma of the ureter  
  - Urothelial Carcinoma of the Prostate  
  - Primary Carcinoma of the Urethra (urothelial carcinomas only) | YES: 24, NO: 0, ABSTAIN: 1, ABSENT: 3 |
| **External request** | Submission request from Genentech to consider the recent Food and Drug Administration (FDA) approval to support the inclusion of Tecentriq in the treatment of cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. | |
| **BL-H 2 of 4** | **Internal request**  
Review the data for the inclusion of atezolizumab as a first-line chemotherapy for patients who are cisplatin-ineligible with locally advanced or metastatic disease.  
**External request**  
Submission request from Genentech to consider the recent Food and Drug Administration (FDA) approval to support the inclusion of Tecentriq in the treatment of cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. | **External request**  
Submission request from Genentech to consider the recent Food and Drug Administration (FDA) approval to support the inclusion of Tecentriq in the treatment of cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. |
| **BL-H 2 of 4** | Based on the available data, the panel consensus was to include pembrolizumab as a subsequent systemic therapy for locally advanced or metastatic disease. Pembrolizumab was added as a category 1 option for the following settings:  
  - Bladder Cancer  
  - Upper GU Tract Tumors: Renal Pelvis  
  - Upper GU Tract Tumors: Urothelial carcinoma of the ureter  
  - Urothelial Carcinoma of the Prostate  
  - Primary Carcinoma of the Urethra (urothelial carcinomas only) | YES: 23, NO: 0, ABSTAIN: 2, ABSENT: 3 |
| Merck & Co, consider adding pembrolizumab as a second-line systemic therapy for advanced or metastatic urothelial cancer (category1). | See Submission for references. |  |  |  |